21 Invest Launches the First Fund Dedicated to the Healthcare Sector, with a Closing of 70 Million and a Target of 150 Million

21 Invest, a European investment group founded in Italy in 1992 by Alessandro Benetton to invest in mid-market companies and help them grow.

Three weeks after acquiring the majority of Rocamed SAM in France, a medtech company specializing in endo-urological medical devices, yesterday November 21st, it announced the launch of the 21 Invest Healthcare fund, the group’s first specialized vehicle dedicated to the healthcare sector.

The fund pursues an impact investment strategy, classified as a fund pursuant to Article 9 of the European SFDR regulation, and closed its first collection at 70 million euros against a maximum target of 150 million.

21 Invest Fund will focus on innovation

21 Invest Healthcare, which has already received support from relief investors such as Fondo Italiano and European Investment Fund, will invest between ten and fifteen million per operation, focusing on Italian and European companies with high growth potential. The companies observed are specialized in innovative products and services for the well-being of people and animals, in the healthcare, wellness and wellbeing sectors, including nutraceuticals, advanced cosmetics, the veterinary sector and similar, explained 21 Invest.

“An important year for 21 Invest, which has consolidated its solid roots and at the same time projects itself towards a future in which the medical sector will be increasingly central, requiring commitment and attention,” said Benetton. “This fund represents our contribution to a crucial area for society and collective well-being, leveraging the experience developed in recent years in Italy and France.”

Benetton is referring to two previous investments made in the medical and pharmaceutical fields with the French PLG, which has gone from being a niche company to a global company providing regulatory and pharmacovigilance services for major pharmaceutical companies, and the Italian Sifi, whose capital was acquired by 21 Invest in April 2015 which recently obtained approval from the EMA for the drug Akantior, developed for the treatment of a rare corneal infection that can cause blindness.

Stefania Petruccioli , Alessandro Damiano , Fabio Parisi are the partners who, together with the principal Michele Fodde, make up the team of professionals with private equity experience and knowledge of the medical sector who will follow the activities of the new fund.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Be Beez. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.